1. Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.
- Author
-
Huang C, Tang TL, Qiu YY, Lin YP, Chen SL, Zhao RZ, Shi GQ, Liao SQ, Chen JH, Fu HY, Liu JZ, Xu BH, Liu TB, and Yang Y
- Subjects
- Humans, Rituximab therapeutic use, Retrospective Studies, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local radiotherapy, Recurrence, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Treatment Outcome, Lymphoma, B-Cell drug therapy, Lymphoma, B-Cell radiotherapy, Lymphoma, Large B-Cell, Diffuse drug therapy
- Abstract
Background: Radiotherapy (RT) is an effective and available local treatment for patients with refractory or relapsed (R/R) aggressive B-cell lymphomas. However, the value of hypofractionated RT in this setting has not been confirmed., Methods: We retrospectively analyzed patients with R/R aggressive B-cell lymphoma who received hypofractionated RT between January 2020 and August 2022 at a single institution. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and acute side effects were analyzed., Results: A total of 30 patients were included. The median dose for residual disease was 36 Gy, at a dose per fraction of 2.3-5 Gy. After RT, the ORR and complete response (CR) rates were 90% and 80%, respectively. With a median follow-up of 10 months (range, 2-27 months), 10 patients (33.3%) experienced disease progression and three died. The 1-year OS and PFS rates for all patients were 81.8% and 66.3%, respectively. The majority (8/10) of post-RT progressions involved out-of-field relapses. Patients with relapsed diseases, no response to systemic therapy, multiple lesions at the time of RT, and no response to RT were associated with out-of-field relapses. PFS was associated with response to RT (P = 0.001) and numbers of residual sites (P < 0.001). No serious non-hematological adverse effects (≥ grade 3) associated with RT were reported., Conclusion: These data suggest that hypofractionated RT was effective and tolerable for patients with R/R aggressive B-cell lymphoma, especially for those that exhibited localized residual disease., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF